Protic Mladjan, Veljkovic Radovan, Bilchik Anton J, Popovic Ana, Kresoja Milana, Nissan Aviram, Avital Itzhak, Stojadinovic Alexander
Clinic of Abdominal, Endocrine and Transplantation Surgery, Clinical Center of Vojvodina, Novi Sad, Serbia.
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Surg Endosc. 2017 Feb;31(2):704-713. doi: 10.1007/s00464-016-5024-5. Epub 2016 Jun 20.
Various mechanisms, including somatic and visceral nociceptive stimulation, have been suggested as a cause for pain after laparoscopic cholecystectomy (LC). We therefore conducted a prospective randomized controlled trial (PRCT) to evaluate whether somatovisceral pain blockade reduces pain after LC.
Analgesic efficacy of multimodal analgesia is superior to standard analgesia for patients undergoing elective LC for symptomatic cholelithiasis. Specifically, topical cystic plate and port-site injection with 0.25 % bupivacaine significantly reduces pain after LC.
This study was designed as single-blinded PRCT.
This study was conducted in an academic medical center.
Between February and May 2010 we randomly assigned 63 patients with symptomatic cholelithiasis in a 1:1 ratio to non-opioid/opioid analgesic combinations (Control Group, n = 32) and non-opioid/opioid analgesic combinations plus topical 0.25 % bupivacaine onto the cystic plate and local 0.25 % bupivacaine port-site injection, post-LC (Study Group, n = 31). Primary endpoint was patient-reported pain 1, 4, 6, 12, 24 h and 1 week post-LC using the Visual Analog Scale (VAS 0-10).
Study groups were comparable clinicopathologically. There were no adverse events. A statistically significant reduction in mean pain score was apparent in Study Group patients in comparison with Control Group (mean VAS 4.83 ± 2.33 vs. 6.80 ± 1.87; p < 0.001) at all early (1-6 h) post-operative time points following LC.
This PRCT shows significantly improved pain control with somatovisceral pain blockade over non-opioid/opioid analgesic combinations following LC for symptomatic cholelithiasis. For centers not utilizing adjunctive local anesthetic for LC, this topical use of bupivacaine may improve patient comfort during recovery. This trial was registered on www.ClinicalTrials.gov NCT# 01972620.
包括躯体和内脏伤害性刺激在内的多种机制已被认为是腹腔镜胆囊切除术(LC)后疼痛的原因。因此,我们进行了一项前瞻性随机对照试验(PRCT),以评估躯体-内脏疼痛阻滞是否能减轻LC后的疼痛。
对于因症状性胆石症接受择期LC的患者,多模式镇痛的镇痛效果优于标准镇痛。具体而言,用0.25%布比卡因局部注射胆囊板和穿刺孔部位可显著减轻LC后的疼痛。
本研究设计为单盲PRCT。
本研究在一家学术医疗中心进行。
2010年2月至5月期间,我们将63例症状性胆石症患者按1:1的比例随机分为非阿片类/阿片类镇痛组合组(对照组,n = 32)和非阿片类/阿片类镇痛组合加LC后在胆囊板局部使用0.25%布比卡因及在穿刺孔部位局部注射0.25%布比卡因组(研究组,n = 31)。主要终点是使用视觉模拟量表(VAS 0-10)评估患者在LC后1、4、6、12、24小时及1周时报告的疼痛情况。
研究组在临床病理方面具有可比性。未发生不良事件。与对照组相比,研究组患者在LC后的所有早期(1-6小时)术后时间点的平均疼痛评分均有统计学意义的显著降低(平均VAS分别为4.83±2.33和6.80±1.87;p < 0.001)。
这项PRCT表明,对于症状性胆石症患者,LC后采用躯体-内脏疼痛阻滞的疼痛控制效果明显优于非阿片类/阿片类镇痛组合。对于未在LC中使用辅助局部麻醉的中心,这种布比卡因的局部应用可能会改善患者恢复期间的舒适度。本试验已在www.ClinicalTrials.gov上注册,NCT编号为01972620。